Literature DB >> 10656807

Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability.

T Buschmann1, T Minamoto, N Wagle, S Y Fuchs, V Adler, M Mai, Z Ronai.   

Abstract

Identification of Mdm2 and JNK as proteins that target degradation of wt p53 prompted us to examine their effect on mutant p53, which exhibits a prolonged half-life. Of five mutant p53 forms studied for association with the targeting molecules, two no longer bound to Mdm2 and JNK. Three mutant forms, which exhibit high expression levels, showed lower affinity for association with Mdm2 and JNK in concordance with greater affinity to p14(ARF), which is among the stabilizing p53 molecules. Monitoring mutant p53 stability in vitro confirmed that, while certain forms of mutant p53 are no longer affected by either JNK or Mdm2, others are targeted for degradation by JNK/Mdm2, albeit at lower efficiency when compared with wt p53. Expression of wt p53 in tumor cells revealed a short half-life, suggesting that the targeting molecules are functional. Forced expression of mutant p53 in p53 null cells confirmed pattern of association with JNK/Mdm2 and prolonged half-life, as found in the tumor cells. Over-expression of Mdm2 in either tumor (which do express endogenous functional Mdm2) or in p53 null cells decreased the stability of mutant p53 suggesting that, despite its expression, Mdm2/JNK are insufficient (amount/affinity) for targeting mutant p53 degradation. Based on both in vitro and in vivo analyses, we conclude that the prolonged half-life of mutant p53 depends on the nature of the mutation, which either alters association with targeting molecules, ratio between p53 and targeting/stabilizing molecules or targeting efficiency. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656807     DOI: 10.1006/jmbi.1999.3387

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

3.  Fam83F induces p53 stabilisation and promotes its activity.

Authors:  Mohammed Salama; Diego Benitez-Riquelme; Seham Elabd; Leonel Munoz; Ping Zhang; Matthias Glanemann; Maria Caterina Mione; Robert Goldin; Thierry Soussi; Gary Davidson; Christine Blattner
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828

4.  p53 binding prevents phosphatase-mediated inactivation of diphosphorylated c-Jun N-terminal kinase.

Authors:  Pramod S Gowda; Fuchun Zhou; Linda V Chadwell; Donald G McEwen
Journal:  J Biol Chem       Date:  2012-03-30       Impact factor: 5.157

5.  Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Authors:  Dun Li; Natalia D Marchenko; Ramona Schulz; Victoria Fischer; Talia Velasco-Hernandez; Flaminia Talos; Ute M Moll
Journal:  Mol Cancer Res       Date:  2011-04-08       Impact factor: 5.852

6.  In vivo anti-tumor effect of expressing p14ARF-TAT using a FGF2-targeted cationic lipid vector.

Authors:  Guoqin Niu; Wouter H P Driessen; Sean M Sullivan; Jeffrey A Hughes
Journal:  Pharm Res       Date:  2011-01-19       Impact factor: 4.200

7.  ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation.

Authors:  Goro Sashida; Yan Liu; Shannon Elf; Yasuhiko Miyata; Kazuma Ohyashiki; Miki Izumi; Silvia Menendez; Stephen D Nimer
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

Review 8.  Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2.

Authors:  Toshinori Ozaki; Mizuyo Nakamura; Osamu Shimozato
Journal:  Biomolecules       Date:  2015-10-23

9.  AKT regulates NPM dependent ARF localization and p53mut stability in tumors.

Authors:  Garth Hamilton; Aswin G Abraham; Jennifer Morton; Oliver Sampson; Dafni E Pefani; Svetlana Khoronenkova; Anna Grawenda; Angelos Papaspyropoulos; Nigel Jamieson; Colin McKay; Owen Sansom; Grigory L Dianov; Eric O'Neill
Journal:  Oncotarget       Date:  2014-08-15

10.  Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?

Authors:  Eziafa I Oduah; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2020-02-10       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.